Natera, Inc. (NASDAQ:NTRA) Receives $184.63 Average PT from Analysts

Natera, Inc. (NASDAQ:NTRA - Get Free Report) has earned a consensus recommendation of "Buy" from the fifteen brokerages that are presently covering the firm, Marketbeat.com reports. Fifteen equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have covered the stock in the last year is $184.63.

Several brokerages recently weighed in on NTRA. Piper Sandler upped their target price on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Barclays upped their target price on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Finally, UBS Group upped their target price on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th.

Natera Stock Performance

Shares of NTRA stock traded down $4.48 during mid-day trading on Thursday, reaching $138.90. 1,377,206 shares of the company's stock traded hands, compared to its average volume of 1,422,396. Natera has a 12 month low of $92.14 and a 12 month high of $183.00. The firm has a 50 day moving average price of $160.33 and a two-hundred day moving average price of $158.16. The firm has a market capitalization of $18.97 billion, a PE ratio of -94.49 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. Natera's quarterly revenue was up 36.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.56) EPS. As a group, equities analysts expect that Natera will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Natera news, Director Gail Boxer Marcus sold 4,299 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the transaction, the director owned 8,118 shares in the company, valued at $1,358,628.48. The trade was a 34.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 6,980 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $150.10, for a total value of $1,047,698.00. Following the transaction, the chief executive officer owned 185,182 shares of the company's stock, valued at $27,795,818.20. This trade represents a 3.63% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,272 shares of company stock worth $8,345,368. Corporate insiders own 7.60% of the company's stock.

Institutional Trading of Natera

Several institutional investors and hedge funds have recently modified their holdings of the stock. Ninety One UK Ltd raised its stake in Natera by 149.1% in the second quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company's stock worth $95,111,000 after buying an additional 336,985 shares in the last quarter. Truist Financial Corp grew its holdings in Natera by 14.3% in the second quarter. Truist Financial Corp now owns 36,248 shares of the medical research company's stock worth $6,124,000 after purchasing an additional 4,525 shares during the last quarter. Poinciana Advisors Group LLC grew its holdings in Natera by 8.5% in the second quarter. Poinciana Advisors Group LLC now owns 1,912 shares of the medical research company's stock worth $323,000 after purchasing an additional 149 shares during the last quarter. V Square Quantitative Management LLC purchased a new position in Natera in the second quarter worth $53,000. Finally, SeaBridge Investment Advisors LLC raised its stake in Natera by 6.1% in the 2nd quarter. SeaBridge Investment Advisors LLC now owns 22,374 shares of the medical research company's stock worth $3,780,000 after acquiring an additional 1,283 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.